TrialBlood advances2026

Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

Takaaki Ono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.